Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.

  • Susan L Lucak
  • Published 2010 in Therapeutic advances in gastroenterology

Abstract

Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder that causes a range of symptoms. Currently, alosetron hydrochloride (Lotronex®), a selective serotonin type 3 receptor antagonist, is the only medication approved for the treatment of severe diarrhea-predominant irritable bowel syndrome (IBS-D) in women who have… (More)
DOI: 10.1177/1756283X10362277

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics